Over the past few years, there has been a significant increase in the number of people taking glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss. While some GLP-1 medications are FDA-approved to treat obesity, others are being used off-label for their weight loss benefits. One common side effect of taking these medications is nausea. Researchers from the Monell Chemical Senses Center have identified a specific population of neurons in the brain that could play a key role in appetite suppression with GLP-1 drugs without causing nausea.
A recent poll found that 12% of Americans have taken a GLP-1 medication, highlighting the growing popularity of these drugs for weight loss. Despite the effectiveness of GLP-1 medications in promoting weight loss, nausea remains a common side effect experienced by many users. The study conducted by researchers at Monell Chemical Senses Center aimed to understand the neural circuits involved in appetite suppression and weight loss due to GLP-1 drugs, separate from those responsible for causing nausea.
The researchers focused on hindbrain GLP-1R neurons, which are a specific population of neurons that play a crucial role in mediating the effects of GLP-1 drugs. Through their study using a mouse model, the researchers found that these neurons react to stimuli that are either nutritive or aversive, with different regions of the hindbrain responding to these stimuli in distinct ways. They discovered that activation of GLP-1R neurons in a region known as the area postrema leads to nausea, while activation in another region called the nucleus tractus solitarius results in satiety without nausea.
The implications of these findings are promising for the development of more selective weight loss drugs based on GLP-1. By targeting the specific population of neurons in the brain that promote satiety without causing nausea, researchers hope to create medications that are more tolerable for users. This could potentially lead to a significant advancement in the treatment of obesity, as current GLP-1 medications have been associated with nausea in a substantial percentage of patients.
Both Shruti Pandiri, MD, and Mir Ali, MD, who specialize in endocrinology and bariatric surgery respectively, see the potential of this discovery in improving the tolerability of GLP-1 medications for weight loss. Pandiri notes that reducing the side effects associated with these medications, such as nausea, could lead to better patient adherence and outcomes in the management of obesity. Ali emphasizes the importance of considering the impact of changes in medication on gastrointestinal effects and overall effectiveness in promoting weight loss.
For individuals taking GLP-1 medications and experiencing nausea, health experts recommend strategies to help minimize this side effect while still benefiting from the weight loss effects of the drugs. These include taking the medication with food, starting with a low dose and gradually increasing it, staying hydrated, eating bland foods, consuming smaller portions, and seeking anti-nausea medication from a healthcare provider. By addressing these challenges associated with GLP-1 medications, researchers and healthcare professionals aim to optimize the use of these drugs in promoting healthy weight loss for individuals seeking to manage obesity.
